Thursday 16 October, 2025
Objectives: Semi-physiological covariate models (SPCMs) describe the maturation of plasma clearance (CLp) for specific metabolic or elimination pathways [1,2]. These…
Read morePoster: Drug/Disease modeling - Paediatrics
Model-based extrapolation and dosing recommendation for raxibacumab in children from birth to <18 years of age
Thursday 16 October, 2025
Objectives: Raxibacumab is a fully humanised monoclonal antibody that blocks the protective antigen-receptor interaction of B. anthracis, thereby protecting target…
Read morePopulation Pharmacokinetic Meta-Analysis of the Antiretroviral Agent Lamivudine in HIV-Infected Children
Thursday 16 October, 2025
Objectives: Lamivudine (3TC), a key nucleoside reverse transcriptase inhibitor (NRTI) against human immunodeficiency virus (HIV), is currently approved for twice…
Read morePharmacokinetic-pharmacodynamic (PKPD) modelling of meropenem in plasma and cerebrospinal fluid (CSF) in infants with late-onset sepsis and/or bacterial meningitis
Thursday 16 October, 2025
Objectives: Meropenem is used off-label in the treatment of late-onset sepsis (LOS) and meningitis in infants. We aimed to develop…
Read moreAn Argument for Standardised Scaling: Comparison of Methods for Scaling Clearance in Children
Thursday 16 October, 2025
Objectives: Clearance changes with both body size (usually measured by weight) and age due to maturation of processes such as…
Read moreMechanistic Modelling of Total Body CD4 T-cell Counts from Paediatric HIV Patients Undergoing Planned Treatment Interruption
Thursday 16 October, 2025
Objectives: Paediatric T-cell population dynamics are influenced by higher thymic output and peripheral T-cell division rates than in adults. CD4…
Read morePopulation pharmacokinetic analysis of fluconazole in premature infants
Thursday 16 October, 2025
Objectives: Fluconazole prophylaxis is an efficacious therapeutic strategy to reduce invasive candidiasis mortality rates in premature infants with extremely low…
Read moreOptimal design in the analysis of a clinical study in paediatric population
Thursday 16 October, 2025
Introduction: A safety dose ranging study that included a 3 days treatment period with 7 PK samples collected each day was…
Read moreHow modelling & simulation supported the drug development in children for a drug S
Thursday 16 October, 2025
Introduction: A study was conducted in paediatric patient population with drug S (marketed in adult), 80 % metabolized via CYP3A4….
Read morePaediatric PK predictions and population analysis
Thursday 16 October, 2025
Introduction: The “first dose in children” can be determined by either Physiollogically based PharmacoKinetics model (PBPK) or compartmental approach using allometric…
Read more